
UTAH MEDICAL PRODUCTS INC
93
Recent developments include quarterly earnings reports showing mixed results, dividend increases, and sales updates reflecting operational challenges and strategic acquisitions.
- UTMD increased its regular quarterly dividend to $0.315 per share as of November 3, 2026 [N1].
- Q3 2026 earnings rose year-over-year driven by lower costs and the Orion acquisition [N2].
- Q3 2026 net sales were reported at $8.621 million [N3].
- Q2 2026 earnings declined year-over-year due to customer losses [N4].
- Cash dividends were announced in mid-2026, reflecting ongoing shareholder returns [N5].
- Q1 2026 earnings fell year-over-year due to elevated litigation costs [N6].
- Q4 2025 earnings were negatively impacted by a decline in OEM sales [N8].
Utah Medical Products, Inc. (UTMD) develops and manufactures medical devices that emphasize patient safety and improved clinical outcomes, primarily serving neonatal intensive care units, labor and delivery departments, and women's health centers. The company leverages multidisciplinary engineering expertise to produce differentiated devices that offer incremental improvements over existing clinical approaches. UTMD sells its products through direct channels in the U.S. and internationally via subsidiaries and a network of approximately 200 distributors. The company has expanded through acquisitions, which accounted for over half of its 2025 sales. UTMD maintains strong liquidity and a history of shareholder returns through dividends and share repurchases [S1][S2].
Utah Medical Products, Inc. is a medical device manufacturer specializing in cost-effective, safety-focused devices primarily for critical care and women's health markets. The company operates globally through direct sales and distributor partnerships, with a history of acquisitions contributing significantly to sales. As of September 30, 2026, UTMD reported strong liquidity with $85.2 million in cash and a current ratio of 21.23. Recent quarterly earnings showed mixed results with Q3 2026 earnings rising year-over-year due to lower costs and acquisitions, while earlier quarters faced challenges from litigation costs and customer losses. The company continues to return capital to shareholders through dividends, recently increasing its quarterly dividend to $0.315 per share [S1][S2][N1][N2][N3][N4][N6][N8]. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
UTMD's ability to integrate multiple engineering disciplines to develop differentiated, safety-focused medical devices addresses critical clinical needs, potentially supporting stable demand in specialized healthcare segments. The company's global distribution network and history of acquisitions provide diversification and market reach. Strong liquidity and consistent shareholder returns through dividends reflect financial discipline and operational stability [S1][S2][N1][N2].
UTMD faces risks from customer losses and litigation costs, which have negatively impacted recent quarterly earnings. Dependence on OEM sales and trade disruptions have also pressured margins and revenues in past periods. The medical device industry is subject to regulatory and competitive challenges that could affect product acceptance and sales. Variability in earnings and sales trends highlight operational risks [N4][N6][N8].
UTMD's moat derives from its specialized focus on safety-enhancing medical devices for critical care and women's health, supported by integrated engineering capabilities across electronics, software, and materials. Its established global distribution network, including direct sales and partnerships with numerous distributors, and a track record of successful acquisitions provide product and channel diversification. The company's reputation for cost-effective, clinically differentiated devices and longstanding relationships with clinicians and customers contribute to competitive advantages [S1].
• Customer Concentration and Losses: Recent earnings declines have been attributed to customer losses, indicating potential risk from dependence on key customers [N4].
• Litigation Costs: Elevated litigation costs have negatively impacted earnings, posing financial and operational risks [N6].
• OEM Sales Decline: Declines in OEM sales have hurt earnings and may reflect competitive or market challenges [N8].
• Trade Disruptions and Margin Pressure: Trade disruptions have contributed to earnings dips and margin squeezes, affecting profitability [N8].
• Regulatory and Competitive Risks: The medical device industry is highly regulated and competitive, which may affect product development, approval, and market acceptance [S1].
Business trends: UTMD focuses on safety-enhancing medical devices for critical care and women's health, with growth supported by acquisitions and global distribution.
Execution milestones: Recent quarters show earnings variability influenced by acquisitions, litigation costs, and customer dynamics; dividend increases reflect capital return strategy.
Key risks: Customer losses, litigation expenses, OEM sales declines, and regulatory challenges pose operational and financial risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Utah Medical Products, Inc. (UTMD) produces high quality, cost-effective medical devices focused on safety and improved patient outcomes, primarily for critical care areas such as neonatal intensive care units, labor and delivery departments, and women's health centers in hospitals, as well as outpatient clinics and physician offices [S1].
- UTMD's business model involves recognizing clinical needs, designing or acquiring economical solutions with regulatory approval, manufacturing reliable devices, and selling through direct channels or partnerships with distributors [S1].
- The company integrates multiple engineering disciplines including electronics, software, mechanical assembly, plastics processing, and materials to create differentiated medical devices that improve patient safety, clinical outcomes, and cost-effectiveness [S1].
- UTMD sells devices directly in the U.S. and internationally through subsidiaries and approximately 200 distributors in major developed and underdeveloped countries, with significant operations in Canada, UK, France, Ireland, Australia, and New Zealand [S1].
- The company has a history of acquisitions and expansions including Columbia Medical, Gesco International neonatal product line, Abcorp, Femcare Holdings Ltd, and others, which contributed 57% of consolidated 2025 sales [S1].
- UTMD has returned significant capital to shareholders since 1992 through share repurchases ($156 million) and cash dividends ($90 million) [S1].
- As of September 30, 2026, UTMD reported cash and cash equivalents of $85.2 million, current assets of $100.6 million, and current liabilities of $4.74 million, resulting in a strong current ratio of 21.23 and cash ratio of 17.98, indicating strong liquidity [S2].
- Net income for the quarter ended September 30, 2026 was $2.787 million with basic and diluted EPS of $0.88 per share [S2].
- Recent quarterly earnings showed variability: Q3 2026 earnings rose year-over-year due to lower costs and the Orion acquisition [N2].
- Q3 2026 net sales were reported at $8.621 million [N3].
- Q2 2026 earnings declined year-over-year due to customer losses [N4].
- Q1 2026 earnings fell year-over-year due to elevated litigation costs [N6].
- Q4 2025 earnings were negatively impacted by a decline in OEM sales [N8].
- UTMD increased its regular quarterly dividend to $0.315 per share as of November 3, 2026 [N1].
- The company announced cash dividends and ex-dividend dates in multiple recent news items, reflecting ongoing shareholder returns [N5, N7].
Generated 2026-11-13
- S1 | 2026-03-27 | 10-K
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-11-03 | www.nasdaq.com | Utah Medical Products, Inc. Increases Regular Quarterly Dividend to $.315 Per Share | https://www.nasdaq.com/articles/utah-medical-products-inc-increases-regular-quarterly-dividend-315-share
- N2 | 2026-10-28 | www.nasdaq.com | UTMD's Q3 Earnings Rise Y/Y on Lower Costs, Orion Acquisition | https://www.nasdaq.com/articles/utmds-q3-earnings-rise-y-y-lower-costs-orion-acquisition
- N3 | 2026-10-22 | www.nasdaq.com | Utah Medical Products, Inc. Reports 3Q 2026 Net Sales of $8,621 | https://www.nasdaq.com/articles/utah-medical-products-inc-reports-3q-2026-net-sales-8621
- N4 | 2026-07-29 | www.nasdaq.com | Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses | https://www.nasdaq.com/articles/utah-medicals-q2-earnings-down-y-y-due-customer-losses
- N5 | 2026-06-15 | www.nasdaq.com | Cash Dividend On The Way From Utah Medical Products (UTMD) | https://www.nasdaq.com/articles/cash-dividend-way-utah-medical-products-utmd
- N6 | 2026-04-29 | www.nasdaq.com | Utah Medical's Q1 Earnings Fall Y/Y Due to Elevated Litigation Costs | https://www.nasdaq.com/articles/utah-medicals-q1-earnings-fall-y-y-due-elevated-litigation-costs
- N7 | 2026-03-28 | www.nasdaq.com | Ex-Dividend Date Nearing for These 10 Stocks – Week of December 16, 2024 | https://www.nasdaq.com/articles/ex-dividend-date-nearing-these-10-stocks-week-december-16-2024
- N8 | 2026-02-04 | www.nasdaq.com | Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y | https://www.nasdaq.com/articles/utah-medicals-q4-earnings-hurt-oem-decline-fall-y-y
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


